HRTH yields 502.23% · JNJ yields 2.14%● Live data
📍 HRTH pulled ahead of the other in Year 1
Combined, HRTH + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HRTH + JNJ for your $10,000?
Harte Hanks, Inc. provides various multi-channel marketing services in the United States and internationally. The company provides agency services, such as customer engagement solutions in direct and digital communications for consumer and business-to-business markets; digital services, including search engine management, display, digital analytics, website development and design, digital strategy, social media, email, e-commerce, and interactive relationship management services; and database marketing and business-to-business markets that offer insight and analytics, customer data integration, and marketing communications tools. It also provides direct marketing services, including digital printing, print on demand, advanced mail optimization, logistics and transportation optimization, tracking, commingling, shrink wrapping, and specialized mailing services, as well as custom kitting, product recalls, and freight optimization services through its fulfillment centers; and operates tele-service workstations, which offer contact center solutions comprising speech, voice and video chat, integrated voice response, analytics, social cloud monitoring, and web self-services. The company provides its services primarily to the retail, B2B, financial services, consumer, and healthcare vertical markets. Harte Hanks, Inc. was founded in 1923 and is headquartered in Austin, Texas.
Full HRTH Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.